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Abstract
Background and aims: South Asian (SA) individuals are thought to represent a group that is at 
high-risk for atherosclerotic cardiovascular disease (ASCVD). However, the performance of the 
Pooled Cohort Equations (PCE) remains uncertain in SAs living in the US. We aimed to study the 
interplay between predicted 10-year ASCVD risk and coronary artery calcium (CAC) in SAs 
compared to other racial/ethnic groups.
Methods: We studied 536 SAs from the Mediators of Atherosclerosis in South Asians Living in 
America (MASALA) study, and 2,073 Non-Hispanic Whites (NHWs), 1,514 African Americans 
(AAs), 1,254 Hispanics, and 671 Chinese Americans (CAs) from the Multi-Ethnic Study of 
Atherosclerosis (MESA) who were not currently on statins. We used logistic regression models to 
assess the association between race/ethnicity and CAC within each ASCVD risk stratum.
Results: SAs at low and at intermediate estimated ASCVD risk were more likely to have CAC 
=0 compared to NHWs, while SAs at high risk had a similar CAC burden to NHWs. For example, 
intermediate-risk SAs had a 73% higher odds of CAC =0 compared to NHWs (95% 1.00–2.99), 
while high-risk SAs were equally likely to have CAC =0 (OR 0.95, 95% CI 0.65–1.38) and CAC 
>100 (OR 0.86, 95% CI 0.61–1.22).
Conclusions: Our results suggest that the extent of ASCVD risk overestimation using the PCEs 
may be even greater among SAs considered at low and intermediate risk than among NHWs. 
Studies with incident ASCVD events are required to validate and/or recalibrate current ASCVD 
risk prediction tools in this group.
Keywords
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Asian
Introduction
South Asian (SA) individuals currently represent the second fastest growing ethnic group in 
the US, with nearly 5 million residents. Several studies have reported a high prevalence of 
cardiovascular risk factors and atherosclerotic cardiovascular disease (ASCVD) in this 
group, the latter being higher among SAs than any other racial/ethnic group living in North 
America or Europe.–
SAs therefore represent a group in whom ASCVD prevention efforts should be intensified.,
However, in the US there is no specific guidance for ASCVD risk assessment in these 
individuals. The 2013 American College of Cardiology / American Heart Association (ACC/
AHA) ASCVD risk assessment guidelines included the pooled cohort equations (PCE), 
which allow estimating 10-year ASCVD risk by race/ethnicity [non-Hispanic Whites 
(NHWs) and African Americans (AAs)] and sex. For other racial/ethnic groups living in the 
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US, including individuals of SA ancestry, the ACC/AHA recommends using the equations 
for NHWs. However, the performance of the equations and their potential for over- or 
underestimation of ASCVD risk in this group remains unknown.
To date, there is no study on SAs living in the US with sufficient follow-up length to allow a 
formal 10-year validation of the 2013 ACC/AHA PCE. The Mediators of Atherosclerosis in 
South Asians Living in America (MASALA) study enrolled individuals of SA ancestry in 
the US and assessed coronary artery calcium (CAC) burden., CAC is a robust predictor of 
ASCVD events– and, in the absence of prospective ASCVD outcomes, provides an 
opportunity to conduct a preliminary evaluation of the performance of the risk estimator in 
SA individuals.
The aim of our study was therefore to evaluate, in a representative population of SAs in the 
US, the interrelationship between 10-year ASCVD risk estimates (using the 2013 
ACC/AHA PCE for NHWs) and CAC burden. Specifically, we assessed the prevalence of 
clinically relevant CAC categories such as a CAC score of 0 (which is known to be 
associated with very low event rates) and a CAC score >100 (which is associated with high 
ASCVD event rates approaching secondary prevention populations). For comparison, we 
performed the same analysis among the 4 racial/ethnic groups included in the similarly-
designed Multi-Ethnic Study of Atherosclerosis (MESA).
Materials and methods
Study design
Full details of the design and methods of the MASALA and MESA studies have been 
reported elsewhere., Briefly, MASALA is a community-based prospective cohort study of 
906 asymptomatic US adults of SA ancestry free from clinical ASCVD, who were enrolled 
from two clinical sites (San Francisco Bay Area at the University of California, San 
Francisco (UCSF) and the greater Chicago area at Northwestern University (NWU). 
MASALA investigators recruited participants of SA ancestry, defined as having at least 3 
grandparents born in India, Pakistan, Bangladesh, Nepal, or Sri Lanka. The first study 
examination began in October 2010, and final participant enrollment was concluded in 
March 2013. The study protocol was designed to be similar to MESA, and was approved by 
the institutional review boards of University of California, San Francisco and Northwestern 
University. All participants provided written informed consent.
MESA is a multi-ethnic, community-based, prospective cohort study of 6,814 men and 
women aged 45 to 84 years who were free from clinical ASCVD at the time of recruitment. 
Study participants were enrolled between July 2000 and September 2002 at six field centers 
in the US and identified themselves as NHW, AA, Hispanic (Latino) or Chinese American 
(CA). The study was approved by the institutional review boards at each center and all 
MESA participants provided written informed consent.
Study population
All participants from MASALA and MESA with information on baseline CAC burden were 
included. Participants from both studies were free of clinical ASCVD at the time of study 
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entry. To assess the performance of the PCE specifically in the population they are intended 
to be used, we excluded participants older than 80 years and those already taking statins. To 
allow direct comparisons between the two studies, MASALA participants aged <45 years 
were also excluded from the analysis as the minimum age of MESA participants at 
enrollment was 45 years. Finally, individuals with missing information on any of the 
variables used by the 2013 ACC/AHA PCE were excluded.
10-year ASCVD risk estimation
In each study participant, 10-year ASCVD risk was estimated using the ACC/AHA 2013 
PCE. Risk estimates for NHWs, Latinos, CAs and SAs were calculated using the equations 
for NHWs men and women, and the corresponding PCE for AA men and women were used 
for ASCVD risk estimates in AAs.
Assessment of coronary artery calcium
Details on the CAC quantification methods implemented in each of the two studies have 
been reported elsewhere. In MESA, CAC was measured was measured using either an 
electronbeam CT (at the Chicago, Los Angeles, and New York centers) or a multidetector 
CT (at the Baltimore, Forsyth County, and St. Paul centers). All images were interpreted at 
the Los Angeles Biomedical Research Center, Torrance, CA. In MASALA, CAC was 
assessed using a cardiacgated electron-beam computed tomography scanner. All images 
were analyzed at the Los Angeles Biomedical Research Center according to MESA study 
methods. In both studies CAC scans were interpreted blinded to race/ethnicity and quantified 
using the Agatston scoring system. In MESA, both intraobserver and interobserver 
agreement for CAC were excellent (kappa statistics, 0.93 and 0.90, respectively). These 
estimates are expected to be similar for MASALA give that identical scanning protocols 
were used and images were interpreted at the same reading center.
Assessment of traditional cardiovascular risk factors
Information on sociodemographic characteristics, tobacco use, family history of coronary 
heart disease, medication use, and physical activity was collected using validated 
questionnaires that were similar for both studies. The body mass index was calculated as 
weight in kilograms divided by height in meters squared. Systolic and diastolic blood 
pressures were measured three times using an automated sphygmomanometer and the mean 
of the last two measurements was used. Lipid profile and plasma glucose levels were 
measured in blood samples collected at baseline and after a 12-hour overnight fast.
Statistical analyses
Baseline demographics, cardiovascular risk factors and 10-year ASCVD risk estimates of 
the study participants were described for each race/ethnicity, both overall and further 
stratified by ASCVD risk score categories. Categorical variables were presented as number 
(%), and continuous variables as mean (SD) or median (IQR) depending on the distribution 
of the data. Differences between racial/ethnic groups were assessed using chi-square tests, t-
tests, and nonparametric tests as appropriate.
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The frequency of ASCVD risk categories (low: <5%, intermediate: 5 to < 7.5%, and high: 
≥7.5%) and the proportion of key, clinically relevant CAC score categories (0 and ≥100) 
were described for each racial/ethnic group adjusted for age. To study the interplay between 
10year ASCVD risk estimates and CAC burden, we also described the distribution of 
clinically relevant age-adjusted CAC categories (0, 1–100, and ≥100) across ASCVD risk 
categories (<5%, ≥5 to 7.5%, and ≥7.5%), for each racial/ethnic group. Chi-square tests 
were used to compare these proportions across each racial/ethnic groups.
To compare CAC group distribution within similar risk groups across race/ethnicity, logistic 
regression was used to evaluate the associations between racial/ethnic groups (NHWs as the 
reference category) and CAC burden categories within each ASCVD risk group. For these 
analyses, dependent variables were CAC = 0 (vs. CAC > 0), and CAC > 100 (vs. CAC ≤ 
100). Analyses were conducted both unadjusted and adjusting for age and sex.
Two sensitivity analyses were conducted. First, we repeated the analyses using alternative 
cutpoints for ASCVD risk categories: low (<5%), intermediate (5–15%), and high (>15%).
Second, we excluded individuals considered to benefit from statin therapy by the ACC/AHA 
2013 guidelines (LDL cholesterol ≥190 mg/dL, and individuals with diabetes and LDL 
cholesterol ≥70 mg/dL) despite the fact that they were not being treated with statins at 
baseline., Third we further adjusted for family history of CHD and education.
A p value <0.05 was considered statistically significant. All analyses were performed using 
Stata version 13 (StataCorp. 2011, College Station, TX).
Results
Study population
We included 536 SAs participants from MASALA, and 5,512 participants from MESA 
(2,073 NHW [37.6%], 1,514 AA [27.5%], 1,254 Hispanics [22.8%], and 671 CA [12.2%]), 
all of whom were not taking statins at baseline and had ages ranging 45–80 years (Figure 1).
Table 1 presents the characteristics of the study participants by racial/ethnic group. 
MASALA participants were on average younger, had a higher educational level, lower 
estimated ASCVD risk, were less likely to smoke, and were less active compared to the 
racial/ethnic groups in MESA (all p <0.05). No clear differences were observed in the 
prevalence of other cardiovascular risk factors between SAs and the other racial/ethnic 
groups.
Supplementary Tables 1–5 display the characteristics of the study participants further 
stratified by baseline 10-year ASCVD estimated risk. Among those at low (<5%) 10-year 
risk similar patterns were noted in the distribution of risk factors as in the overall group 
presented in Table 1. Among higher risk strata the following differences were noted: SAs at 
intermediate risk (5 to <7.5%) were more likely to be male, diabetic, and have higher 
triglyceride levels, while those at high risk (≥7.5%) were also more likely to be male 
compared to MESA participants (all p<0.05).
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Distribution of estimated 10-year ASCVD risk
Figure 2A displays the age-adjusted distribution of 10-year ASCVD risk categories across 
racial/ethnic groups. The prevalence of low, intermediate, and high ASCVD risk was almost 
identical comparing SAs and NHWs.
Burden of CAC in the study population
Figure 2B displays the age-adjusted distribution of key clinically relevant CAC burden 
categories across racial/ethnic groups. The prevalence of CAC was very similar comparing 
SAs to NHWs, with nearly 50% CAC =0 and 25% for CAC 1–100 and >100.
Interplay between 10-year ASCVD risk estimates and CAC burden
Table 2 and Figure 2C present age-adjusted proportions of CAC burden categories by 
ASCVD risk strata and racial/ethnic groups. Among SAs the prevalence of CAC=0 was 
inversely proportional to ASCVD risk (prevalence of CAC =0: 86%, 62%, and 34% for low, 
intermediate and high ASCVD risk groups respectively; p<0.001). Similar trends were noted 
among other race/ethnicities. In contrast, the prevalence of CAC >100 among SAs was 
correlated with estimated ASCVD risk (prevalence of CAC >100: 3%, 6%, and 31% for low, 
intermediate, and high ASCVD risk groups respectively; p < 0.001). The same was true for 
other race/ethnicities. Supplementary Table 6 presents these results using alternative 
ASCVD risk cutpoints (<5%, 5 to 15%, and >15%).
Associations between race/ethnicity and CAC burden within estimated ASCVD risk strata
Table 3 presents the associations between race/ethnicity and CAC categories across 
estimated 10-year ASCVD risk strata. In the low and intermediate ASCVD risk strata, SAs 
had a higher odds of CAC =0 compared to NHWs (ORs 1.26, 95% 0.91–1.76 and 1.73, 95% 
CI 1.00–2.99, respectively). In the high ASCVD risk group, SAs had similar odds of CAC=0 
and CAC >100 compared to NHWs (OR 0.95, 95% CI 0.65–1.38 and 0.86, 95% CI 0.61–
1.22 respectively).
Among other racial/ethnic groups, AAs and Hispanics considered at low ASCVD risk had 
lower odds than NHWs of having CAC>100. Among individuals considered at intermediate 
ASCVD risk, AA and Hispanic ancestries were associated with higher odds of having 
CAC=0 compared to NHWs (ORs 2.23, 95% CI 1.51–3.30 and 1.74, 95% CI 1.14–2.66, 
respectively). In the high-risk stratum, AAs, Hispanics and CAs had higher odds of having 
CAC=0 than NHWs.
Supplementary Table 7 presents the results using alternative ASCVD risk cutpoints (<5%, 
5–15%, and >15%). Similar results were observed in analyses further excluding individuals 
with LDL cholesterol >190 mg/dL and diabetic patients with LDL cholesterol > 70 mg/dL 
(Table 4, Supplementary Table 8). We also obtained similar results after additonally 
adjusting for family history of coronary heart disease and education (Supplementary Table 
9).
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In two community-based study populations of adults living in the US comprising 5 racial/
ethnic groups, a SA ancestry was associated with higher odds of having CAC=0 compared to 
NHWs in the low and in the intermediate risk groups, while SAs in the high risk group had a 
similar distribution of CAC compared to NHWs. These findings have implications for the 
interpretation of ASCVD risk estimates and for the utility of CAC scoring in SAs, a large 
group living in the US in whom optimal ASCVD risk estimation strategy is currently 
uncertain.
Our study has important clinical implications. In the absence of 10-year longitudinal data 
and therefore of specific ASCVD risk equations for SAs in the US, the ACC/AHA currently 
recommends using the 2013 PCE for NHWs to assess 10-year ASCVD risk in this group.
Nevertheless, two considerations lead to great uncertainty when following this strategy. 
First, release in 2013 of the ACC/AHA PCE was followed by concerns regarding their 
potential for global ASCVD risk overestimation.– Second, a number of studies have shown 
SAs having higher event rates than NHWs in almost every country where this has been 
evaluated.,,– In this context, the performance of the 2013 PCE specifically in SAs is unclear. 
Based on our preliminary results, we posit that the PCEs may overestimate risk in low and 
intermediate risk SAs even to a greater extent than they do in NHWs.,
Previous reports comparing MASALA and MESA cohorts have shown SAs from MASALA 
and NHWs from MESA having a similar profile in terms of age-standardized CAC burden at 
baseline., Similar results have been reported in European studies as well. This appears to be 
true particularly among high risk SAs based on results of our study. This may seem in 
contradiction with prior studies conducted in Europe and Canada, which consistently 
showed higher ASCVD event rates in SAs compared to NHWs.,,– Nevertheless, while SAs 
migrants included in those studies tended to have low income, low education, and a high 
burden of cardiovascular risk factors, SAs from MASALA represent a highly educated and 
high income group consistent with the immigration patterns of SAs in the US compared to 
Europe and Canada.
It is therefore possible that MASALA comprised a lower-risk SA subgroup compared to the 
aforementioned studies. MASALA also excluded SAs with a history of clinical ASCVD and 
we further excluded those on statins at baseline enriching our study population with healthy 
SAs. Furthermore, MASALA was initiated 10 years later than MESA, when key prevention 
programs such as anti-tobacco laws had already been instituted, and statin therapies were 
more commonly prescribed for primary prevention., The latter is consistent with our finding 
of a larger proportion of individuals excluded due to baseline statin use in MASALA (30%) 
than in MESA (12–17%). The combination of these factors may explain the greater 
similarity between SAs and NHWs when comparing MESA and MASALA than that 
observed in prior multi-ethnic evaluations.
Study Limitations
Our study has some limitations that are worth discussing. First, the key limitation of our 
analysis is the lack of longitudinal data for SAs, which precluded performing a formal 
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validation study of the PCE. Nevertheless, CAC is considered a robust predictor of CVD 
events, and the CAC burden categories used in our analyses (CAC=0 and CAC>100) have 
shown strong associations with very low and very high ASCVD event rates, respectively.,
Therefore, until 10-year follow-up data is available for SAs, our analysis provides valuable 
preliminary insights on the potential performance that the PCE may have in this important 
group.
Second, the sample size of the SA population was relatively small, particularly after 
excluding individuals using statins, which likely limited statistical power. This may be 
particularly true to low risk SAs who tend to have CAC =0. Nevertheless, we were able to 
identify statistically significant differences in the intermediate risk stratum, which is indeed 
the most likely to benefit from further testing using tools such as CAC. Important 
differences between MESA and MASLA must be acknowledged with direct comparisons 
between the two cohorts. Despite rigorous adjustment for potential confounders, there 
remains the possibility for residual confounding. While the high SES among SAs in the 
MASALA study is consistent with national survey data, it is possible that non-responders or 
those who declined to participate in the study had lower SES thus potentially limiting 
generalizability of the study to SAs of lower SES in the US or SA globally. Finally, as 
discussed above, the exclusion of individuals with a history of ASCVD and those taking 
statins, as well as the 10-year lag between MASALA and MESA initiation may have 
resulted in a healthy SA population and thus results may not be generalizable to all SAs. 
However our study population is a true primary prevention cohort in whom ASCVD risk 
estimation is used to guide the decision to initiate lipid-lowering therapy. , Therefore, our 
results may be used to guide clinicians when interpreting risk estimations and prescribing 
lipid-lowering therapies in this group.
Conclusion
Until prospective information on cardiovascular outcomes becomes available for SA 
individuals living in the US, understanding the relationship between 10-year cardiovascular 
risk estimates and CAC burden provides preliminary insights on the potential performance 
of the PCE in this important racial/ethnic group. Our findings suggest that risk 
overestimation among low and intermediate-risk SAs may be even greater than among their 
NHW counterparts. In this context, CAC may be a very valuable tool to help further refine 
risk estimations in SAs considered at intermediate risk. Validation studies are needed to 
confirm these preliminary 2 findings.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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AA African American
ACC American College of Cardiology
AHA American Heart Association
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CA Chinese American
CAC coronary artery calcium
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1. The performance of the pooled cohort equations (PCE) among South Asians 
(SAs) is uncertain.
2. In the absence of 10-year follow-up data for ASCVD events, coronary artery 
calcium (CAC) may be used as a surrogate outcome.
3. We studied the prevalence of CAC across strata of ASCVD risk in SAs as 
well as in other 4 races/ethnicities.
4. There was a higher odds of CAC=0 among low and intermediate risk SAs as 
compared to NHWs.
5. The PCE may overestimate risk in low and intermediate risk in SAs living in 
the US even to a greater extent than in NHWs.
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Flowchart diagram demonstrating inclusion/exclusion criteria in each cohort to derive the 
final study population We excluded participants older than 80 years and those already taking 
statins.
To allow direct comparisons between the two studies, MASALA participants aged <45 years 
were also excluded from the analysis as the minimum age of MESA participants at 
enrollment was 45 years. Finally, individuals with missing information on any of the 
variables used by the 2013 ACC/AHA PCE were excluded.
Rifai et al. Page 13















(A) Distribution of low (<5%), intermediate (5 to 7.5%) and high (≥7.5%) 10-year estimated 
ASCVD risk categories by racial/ethnic group. (B) Distribution of clinically relevant 
coronary artery calcium categories (0, 1 – 100, >100), by racial/ethnic group. (C) 
Distribution of clinically relevant coronary artery calcium categories (0, 1 – 100, >100), by 
racial/ethnic group and ASCVD risk categories. Data are presented as percentages. AA = 
African American; CA = Chinese American; NHW = Non-Hispanic White; SA = South 
Asian; ASCVD = atherosclerotic cardiovascular risk disease; CAC = coronary artery 
calcium.
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